We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In his fiscal year 2017 budget, President Barack Obama says he will seek more than $1 billion in mandatory funding over two years to help combat prescription opioid abuse. Read More
Two Oregon supplement makers are in the FDA’s crosshairs for marketing their products for a range of unapproved conditions, including regulating blood pressure and alleviating panic attacks. Read More
Turing Pharmaceuticals and Valeant Pharmaceuticals lined “their pockets at the expense of some of the most vulnerable families in our nation,” House Oversight Committee Ranking Member Elijah Cummings (D-Md.) says in a memo to committee members. Read More
In a rare warning letter to an institutional review board, CDER’s Office of Scientific Investigations contends that an IRB at Monmouth Medical Center was lax in supervising research at the facility. Read More
Telesta Therapeutics has received a complete response letter from the FDA, informing the company that its BLA for Mycobacterium phlei cell wall-nucleic acid complex would need an additional Phase 3 clinical trial to adequately establish the candidate’s efficacy and safety. Read More
Wockhardt’s CEO Habil Khorakiwala has characterized the FDA’s recent findings of nine Form 483 observations at its manufacturing plant in Shendra, India as minor, and predicted that the agency’s concerns would be resolved within a few months. Read More
Three stem cell treatment centers have been hit with an FDA warning letter critical of their recordkeeping and lack of required licenses for their clinical procedures. Read More